FierceBiotechOriginal article
{"a":[{"_":"Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout","$":{"href":"/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout","hreflang":"en"}}]}
Negative
AI Analysis
Summary
Pfizer discontinued two clinical-stage obesity programs including a GLP-1 receptor agonist acquired from Metsera and a GIPR antagonist as part of a quarterly pipeline review.
Outcome Details
Pipeline programs discontinued
Importance:4/10
Sentiment:
-0.70
pipeline discontinuationobesityclinical stageGLP-1 agonistGIPR antagonist
Related Companies
Read the original article
Published by FierceBiotech on August 4, 2026 8:47 AM